Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 13;17(1):263-267.
doi: 10.1159/000546616. eCollection 2025 Jan-Dec.

Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report

Yseult Senterre  1 , Amandine Bouillenne  1 , Murielle Sabatiello  2 , Anne-Sophie Demoulin  3 , Arjen F Nikkels  1
Affiliations

Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report

Yseult Senterre et al. Case Rep Dermatol. .

Abstract

Introduction: Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.

Case presentation: A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.

Conclusion: EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.

Keywords: Amivantamab; Case report; Erosive pustular dermatosis; Scalp erosion; Scalp ulceration.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1.
Fig. 1.
a Erosive disseminated lesions of the scalp with accompanying alopecia during amivantamab treatment. b Histology revealing an erosion with an underlying heavy inflammatory infiltrate of neutrophils (H/E, ×15).
Fig. 2.
Fig. 2.
Spontaneous recurrence of the scalp lesions despite discontinuation of amivantamab therapy for 6 months.
See this image and copyright information in PMC

References

    1. Liao Z, Luo C, Huang Y, Jiang Z, Wei H, Wang Y. Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance. Expert Opin Drug Saf. 2025:1–10. - PubMed
    1. Basse C, Chabanol H, Bonte PE, Fromantin I, Girard N. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer. 2022;173:116–23. - PubMed
    1. Petrini I, Giaccone G. Amivantamab in the treatment of metastatic nsclc: patient selection and special considerations. Onco Targets Ther. 2022;15:1197–210. - PMC - PubMed
    1. Nikolaou V, Gerochristou M, Sgontzou T, Silaidi C, Stratigos A. Beneath the surface: novel insights into Amivantamab-induced acneiform rash. Eur J Cancer. 2024;208:114198. - PubMed
    1. George MN, Seervai RNH, Chon SY. Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: a case series. JAAD Case Rep. 2024;47:72–9. - PMC - PubMed